Effect of asthma compliance enhancement training on asthma control in patients on combination therapy with salmeterol/fluticasone propionate: A randomised controlled trial

Clinical Respiratory Journal

Volumn 3, Issue 3, 2009, Pages 161-168

  Ulrik, Charlotte Suppli ^a,i   Claudius, Birgitte Kjor ^b   Tamm, Michael ^c   Harving, Henrik ^d   Siersted, Hans Christian ^e   Backer, Vibeke ^f   Hellquist, Birthe ^g   Dahl, Ronald ^g   Høgholm, Asbjørn ^h   Jøhnk, Ida Karina ^b  

^a HVIDOVRE HOSPITAL   (Denmark)

^b GLAXOSMITHKLINE   (Denmark)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d AALBORG UNIVERSITY HOSPITAL   (Denmark)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

^f BISPEBJERG HOSPITAL   (Denmark)

^g AARHUS UNIVERSITY HOSPITAL   (Denmark)

^h NAESTVED HOSPITAL   (Denmark)

ⁱ NONE   (Denmark)

Author keywords

Adults; Asthma; Asthma control; Combination therapy; Compliance

Indexed keywords

DISKUS; FLUTICASONE PROPIONATE PLUS SALMETEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASTHMA; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCREENING; TRAINING; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ALBUTEROL; ANDROSTADIENES; ASTHMA; BRONCHODILATOR AGENTS; DENMARK; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; PATIENT COMPLIANCE; SWITZERLAND; TREATMENT OUTCOME;

EID: 68849089079     PISSN: 17526981     EISSN: 1752699X     Source Type: Journal    
DOI: 10.1111/j.1752-699X.2009.00129.x     Document Type: Article

References (21)

1. Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2007. Available from http://www.ginasthma.org
2. Rabe KF, Adachi M, Lai CKW, et al. Worldwide severity and control in asthma in children and adults: the global Asthma Insights and Reality surveys. J Allergy Clin Immunol. 2004 114 : 40 7.
3. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma control study. Am J Respir Crit Care Med. 2004 170 : 836 44.
4. Bateman ED, Frith LF, Braunstein GL. Achieving guideline-based asthma control: does the patient benefit? Eur Respir J. 2002 20 : 588 93.
5. O'Byrne PM, Barnes PJ, Rodriquez-Roison R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med. 2001 164 : 1392 7.
6. Rabe KF, Atienza T, Magyar P, et al. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet. 2006 368 : 744 53.
7. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet. 1994 344 : 219 24.
8. Pauwels RA, Lofdahl C-G, Postma DCS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med. 1997 337 : 1405 11.
9. Ulrik CS, Backer V, Søes-Petersen U, et al. The patient's perspective: adherence or non-adherence to asthma controller therapy? J Asthma. 2006 43 : 701 4.
10. Bender B, Milgrom H, Apter A. Adherence intervention research: what have we learned and what do we do next? J Allergy Clin Immunol. 2003 112 : 489 94.
11. Farzanfar R, Finkelstein J, Friedman RH. Testing the usability of two automated home-based patient-management systems. J Med Syst. 2004 28 : 143 53.
12. Gruffydd-Jones K. Quality-of-life measures in asthma - do they matter to the GP? Br J Gen Pract. 1997 47 : 392 4.
13. Moy ML, Israel E, Weiss ST, et al. Clinical predictors of health-related quality of life depend on asthma severity. Am J Respir Crit Care Med. 2001 163 : 924 9.
14. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. Washington (DC): National Institutes of Health, National Heart, Lung, and Blood Institute, 2002 Publication no. 02-3659 EF, Guyatt GH, Ferrie PJ, et al. Measuring quality of life in asthma. Am Rev Respir Dis. 1993 147 : 832 8.
15. Juniper EF, Gyatt GH, Epstein RS, et al. Evaluation of impairment of health-related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax. 1992 47 : 76 83.
16. Partridge MR, Hill SR. On behalf of the 1998 World Asthma Meeting Education and Delivery of Care Working Group. Eur Respir J. 2000 16 : 333 48.
17. Reddel HK. Goals of asthma treatment: how high should we go? Eur Respir J. 2004 24 : 715 7.
18. Suissa S, Ernst P, Benayoun S, et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med. 2000 343 : 332 6. (Pubitemid 30616699)
19. Masoli M, Weatherall M, Holt S, Beasley R. Clinical dose-response relationship of fluticasone propionate in adults with asthma. Thorax. 2004 59 : 16 20.
20. Hawkins G, McMahon A, Twaddle S, et al. Stepping down inhaled corticosteroids in asthma: a randomized controlled trial. Br Med J. 2003 326 : 1115.
21. Buisse W, Koenig S, Oppenheimer J, et al. Steroid-sparing effect of fluticasone propionate 100 microg and salmeterol 50 microg administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 microg administered twice daily. J Allergy Clin Immunol. 2003 111 : 57 65.